reports
- Wedbush Research
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
ACRS ACLARIS THERAPEUTICS INC.
FRX_CN FENNEC PHARMACEUTICALS
TMHC TAYLOR MORRISON HOME CORPORATION
WVE WAVE LIFE SCIENCES
MHO M/I HOMES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
IDYA IDEAYA BIOSCIENCES
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
STUB STUBHUB HOLDINGS INC.
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
ACRS ACLARIS THERAPEUTICS INC.
WVE WAVE LIFE SCIENCES
ANAB ANAPTYSBIO INC.
RCUS ARCUS BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
Texas Capital Bancshares, Inc. Announces Date for Q3 2025 Operating Re...
Texas Capital Bancshares, Inc. Announces Date for Q3 2025 Operating Results DALLAS, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the third quarter of 2025 after market on Wednesday, October 22, 2025. Executive management will host a conference call and webcast to discuss third quarter 2025 operating results on Wednesday, October 22, 2025, at 5:00 p.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number t...
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
STTK SHATTUCK LABS
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient F...
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will host it’s 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025 at 8:00 AM ET to discuss the Company’s progress in addressing therapeutic gaps in immuno-inflammator...
- Wedbush Research
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
CYBR CYBERARK SOFTWARE LTD.
CXW CORECIVIC INC.
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
BLDR BUILDERS FIRSTSOURCE INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
ZS ZSCALER INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
STTK INC.
NUVB SHATTUCK LABS
STX NUVATION BIO INC (A)
ATXS SEAGATE TECHNOLOGY HLDGS PLC
GFS ASTRIA THERAPEUTICS INC
MLTX GLOBALFOUNDRIES INC
SYRE MOONLAKE IMMUNOTHERAPEUTICS
ORKA SPYRE THERAPEUTICS INC.
ORUKA THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
First Northwest Bancorp and First Fed Bank name Curt Queyrouze as CEO ...
First Northwest Bancorp and First Fed Bank name Curt Queyrouze as CEO and President PORT ANGELES, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- First Northwest Bancorp (Nasdaq: FNWB) (“First Northwest”) and its subsidiary First Fed Bank (“First Fed” and, together with First Northwest, the “Company”) are pleased to announce today that Curt Queyrouze will become the Company’s new Chief Executive Officer and President, starting on September 17, 2025. He will also be appointed as a member of the Board of Directors of both First Northwest and First Fed at that time. “It's a privilege ...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
LEN LENNAR CORPORATION CLASS A
INTC INTEL CORPORATION
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
MHO M/I HOMES INC.
PTGX PROTAGONIST THERAPEUTICS
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
SMCI SUPER MICRO COMPUTER
STX INC.
ATXS SEAGATE TECHNOLOGY HLDGS PLC
GFS ASTRIA THERAPEUTICS INC
GMTX GLOBALFOUNDRIES INC
MLTX GEMINI THERAPEUTICS INC
APGE MOONLAKE IMMUNOTHERAPEUTICS
ORKA APOGEE THERAPEUTICS INC
AVTX ORUKA THERAPEUTICS INC
AVALO THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Present...
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress - Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that a late-breaking abstract on its open-label Phase 2a trial of AT...
Aclaris Therapeutics to Participate in Two September Healthcare Confer...
Aclaris Therapeutics to Participate in Two September Healthcare Conferences WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September. On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Canto...
First Fed Foundation Invites Final Applications for Fall Grant Cycle
First Fed Foundation Invites Final Applications for Fall Grant Cycle PORT ANGELES, Wash., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The First Fed Foundation is pleased to remind nonprofit, tribal, government, and school district organizations serving Clallam, Jefferson, Kitsap, Whatcom Counties, and the city of Bellevue that the Fall 2025 grant application cycle is still open—but not much longer. Applications will be accepted through 11:59 PM on Monday, September 1, 2025. About First Fed FoundationFounded in 2015 with a generous $12 million gift in cash and stock from First Northwest Bancorp (NA...
- David Nierengarten
- Dennis Pak
- Martin Fan
Appian Announces Second Quarter 2025 Financial Results
Appian Announces Second Quarter 2025 Financial Results Second quarter cloud subscriptions revenue increased 21% year-over-year to $106.9 million Second quarter total revenue increased 17% year-over-year to $170.6 million MCLEAN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the second quarter ended June 30, 2025. “Appian AI drove strong financial results in the second quarter of 2025, with higher prices and a larger pipeline,” said Matt Calkins, CEO & Founder. Second Quarter 2025 Financial Highlights: Revenue: Cloud subscriptions r...
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and...
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAY...
Appian To Participate in Upcoming Investor Conferences
Appian To Participate in Upcoming Investor Conferences MCLEAN, Va., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN), the leading platform for AI process automation, announced today that management will be presenting and hosting meetings with institutional investors at the following upcoming conferences: Keybanc Technology Leadership ForumMonday August 11, 2025A fireside chat is scheduled for 2:00pm Mountain Time and will be webcast live at the following link: Citi Global TMT ConferenceWednesday September 3, 2025A fireside chat is scheduled for 12:50pm Eastern Time and will ...
- Jonathan Moreland
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
VRNS VARONIS SYSTEMS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
BKNG BOOKING HOLDINGS INC.
SMCI SUPER MICRO COMPUTER
FUBO INC.
U FUBOTV
NUVB UNITY SOFTWARE
STX NUVATION BIO INC (A)
SEAGATE TECHNOLOGY HLDGS PLC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.